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Diamond Blackfan anemia (DBA) is a bone marrow failure syndrome associated with 
heterozygous mutations in the ribosomal protein S19 (RPS19) gene in a subgroup of patients. 
One of the interacting partners with RPS19 is the oncoprotein PIM-1 kinase. We intercrossed 
Rps19+/- and Pim-1-/- mice strains to study the effect from the disruption of both genes. The 
double mutant (Rps19+/-Pim-1-/-) mice display normal growth with increased peripheral white- 
and red blood cell counts when compared to the w.t. mice (Rps19+/+Pim-1+/+). Molecular 
analysis of bone marrow cells in Rps19+/-Pim-1-/- mice revealed up-regulated levels of c-Myc 
and the anti-apoptotic factors Bcl2, BclXL and Mcl-1. This is associated with a reduction of the 
apoptotic factors Bak and Caspase 3 as well as the cell cycle regulator p21. Our findings 
suggest that combined Rps19 insufficiency and Pim-1 deficiency promotes murine myeloid 
cell growth through a deregulation of c-Myc and a simultaneous up-regulation of anti-
apoptotic Bcl proteins. 
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Introduction 
Diamond-Blackfan anemia (DBA) is a rare bone marrow failure characterized by an absence 
or decrease of erythroid precursor cells in the bone marrow but otherwise normal cellularity 
1,2. In DBA, as in several bone marrow failure syndromes, affected individuals have an 
increased risk for developing malignant disease, specifically myelodysplastic syndromes 
(MDS) and acute myeloid leukemia (AML) 1,3,4. Approximately 25% of patients with DBA 
are heterozygous for mutations in the ribosomal protein S19 gene (RPS19) 5 and another 10-
20% of patients carry mutations in different ribosomal protein genes 6 RPS19 deficiency in 
hematopoietic cells is associated with reduced erythroid proliferative capacity 7, mitotic arrest 
in the G0/G1 phase and increased apoptosis of erythroid progenitors 8. Impaired ribosomal 
biogenesis is a distinct feature in the pathophysiology of DBA but the connection to erythroid 
hypoplasia and the predisposition to myeloproliferative disease is unclear 9,10. It is assumed 
that the progression to MDS and leukemia requires additional mutations to reach clonal 
dominance 11. Several factors interact with RPS19 12 one of which is identified as the serine-
threonine kinase PIM-1 13. PIM-1 is ubiquitously present and highly expressed in 
hematopoietic tissues 14 where it promotes cell cycle progression, cell proliferation and 
survival 15,16. The PIM-1 deficient mouse is characterized by microcytotic anemia and 
impaired erythroid colony forming capacity in vitro 17,18. PIM-1 is also recognized as a 
synergistic partner with c-Myc in tumorigenesis 19 and the transcriptional activity of c-Myc is 
dependent on histone phosphorylation by PIM-1 20. Moreover, PIM-1 phosphorylates the 
Cdc25A cell cycle phosphatase, which is a transcriptional target of c-Myc. This links PIM-1-
mediated mitogenic signals to the cell cycle machinery 21. On the other hand, PIM-1 can 
stimulate c-Myc-mediated apoptosis via activation of caspase-3-like proteases downstream of 
c-Myc 22. The proto-oncogene c-Myc has a pivotal role in growth control, differentiation and 
apoptosis. c-Myc can directly promote ribosome biogenesis and protein synthesis rate through 
transcription of several components in the translational machinery 23. This seems to be 
counteracted by the ribosomal protein L11 which suppresses c-Myc activity 24. 
We have previously generated a mouse model with targeted disruption of Rps19 25. The 
Rps19 null mouse is lethal prior to implantation whereas the Rps19 heterozygous mice show a 
normal phenotype 25. To clarify the significance of the previously reported RPS19 and PIM-1 
interaction we generated mice with targeted disruptions of Rps19 and/or Pim-1. We present 
herein the results from the morphological and molecular analysis of hematopoietic organs in 
these mice strains. Our findings support a combined effect of Rps19 and Pim-1 mutations on 
myeloid proliferation. 
 
Materials and methods 
 
Generation of mice carrying Rps19 and Pim-1 disruptions 
Rps19+/- mice 25 were bred with Pim-1-/- mice 18 for several generations on a C57/Bl6 
background to produce offspring with the genotypes Rps19+/+Pim-1+/+, Rps19+/-Pim-1+/+, 
Rps19+/+Pim-1-/- and Rps19+/-Pim-1-/- (n=83). Breeding was approved by the Uppsala Animal 
Research Ethics Board (Dnr C256/4). Mice were genotyped by PCR as described previously 
18,25 (primer sequences are available upon request). 
 
Hematological analysis and bone marrow preparations 
Hematological analysis including hemoglobin concentration (Hb), red- and white blood cell 
count (RBC, WBC), hematocrit (HC), mean erythroid corpuscular volume (MCV) and mean 
erythroid hemoglobin concentration (MCHC) was performed using peripheral blood (EDTA) 
from adult Rps19+/+ Pim-1+/+, Rps19+/- Pim-1+/+, Rps19+/+ Pim-1-/- and Rps19+/- Pim-1-/- mice 
as previously described26. BM cells were collected from Rps19+/+ Pim-1+/+ n=9, Rps19+/- 
Pim-1+/+ n=8, Rps19+/+ Pim-1-/- n=10 and Rps19+/- Pim-1-/- n=6 and pooled. In brief, mice 
femurs were dissected and flushed with +4°C 1xPBS. Following centrifugation at 2000 g for 
5 minutes at +4°C BM cells were resuspended in RIPA lysis buffer (50mM Tris-HCl pH 7.5, 
150mM NaCl, 1% Triton X-100, 1% sodium deoxycholate and 0.1% SDS) supplemented 
with proteasome inhibitor MG132 (1:1 000, SIGMA), phosphatase inhibitor cocktail 1 (1:1 
000, SIGMA), 0.1 mM Sodium vanadate (SIGMA) and protease inhibitor cocktail (1:1 000, 
SIGMA). BM proteins were stored at -20ºC.  
 
Histopathological analysis of bone marrow and spleen 
BM cells were scraped from mice femurs and BM smears were prepared directly in 100% 
fetal bovine serum (FBS, GIBCO. Smears were dried in room temperature before Giemsa 
staining according to standard procedures. Mice spleens were dissected and fixed in 4 % 
formalin over night before paraffin embedding. Embedded spleens were sectioned and stained 
with hematoxylin and eosin according to standard procedures. 
 
Western Blotting 
Total BM proteins were separated on 10 % SDS-polyacrylamide gels (Invitrogen) and 
electrophoretically transferred to PVDF Immobilon-FL membranes (Millipore). Non-specific 
binding was blocked by 1 h incubation with 2% bovine serum albumin (BSA) in PBST (0.1% 
Tween-20 in 1xPBS). Blots were probed with the primary antibodies beta actin (Abcam), Bak 
(Sigma), Bcl2 (Santa Cruz), BclXL (Santa Cruz), Cleaved Caspase 3 (Cell Signaling), c-Myc 
(Santa Cruz), Mcl-1 (Santa Cruz), p21 (Santa Cruz), p53 (Cell Signaling), phosphotyrosine 
(Upstate Biotechnology) and RPS19 (kindly provided by Prof. Fabrizio Loreni, Italy) for 1 h 
in a buffer containing 1% BSA in PBST. After being washed for 3x5 minutes in PBST, blots 
were incubated with Alexa Flour 680 (goat anti-rabbit, Molecular Probes) and IRD-800 
(rabbit anti-mouse, LI-COR Bioscience) conjugated secondary antibodies for 1 h. Following 
washing for 3x5 minutes in PBST and 1x5 minutes in 1xPBS proteins were visualized and 
quantified using the Odyssey infrared imaging system® and software (LI-COR Bioscience). 
All proteins are measured at least twice and normalized to beta-actin levels.  
 
Reverse transcription and quantitative real time PCR 
Red blood cells in the BM samples were lyzed by EasyLyse erythrocyte lysis buffer 
(Universal Biologicals). Total RNA was prepared using TRIzol reagent (Invitrogen) 
according to the manufacturer’s recommendations. cDNA was synthesised using a 
RevertAidTM H Minus First Strand cDNA Synthesis Kit (Fermentas) according to 
manufacturers protocol. Quantitative real time PCR was performed to analyze Rps19 and 
Pim-1 transcript levels using the Platinum® SYBR® Green qPCR SuperMix-UDG kit 
(Invitrogen) according to manufacturers recommendations. Primer sequences are available 
upon request. 
 
Statistical analysis 
Results are presented as means ± standard deviation. Western blot experiments were 
conducted on pooled material. Quantitative real time PCR experiments were set up in 
triplicates. Each experiment was repeated at least twice. Cell cycle experiments were repeated 
four times. Results were tested for statistical significance using the two-tailed unpaired 
Student t-test. P < 0.05 was considered statistically significant 27. 
Results 
 
Mice with a combined Rps19 and Pim-1 disruption have an increased myeloid/erythroid 
cellularity 
To investigate the functional effect of Rps19 and Pim-1 we generated different combinations 
of Rps19 and Pim-1 genotypes by interbreeding the mice strains Rps19+/- C57BL/6J, Pim-1-/- 
FVB/NJ and wild type C57BL/6J on a pure C57 background. Litters were genotyped showing 
a Mendelian distribution (data not shown) for the six possible genotypes. We selected mice 
with the following genotypes for further analysis: Rps19+/+ Pim-1+/+ (n=22), Rps19+/- Pim-1+/+ 
(n=13), Rps19+/+ Pim-1-/- (n=25) and Rps19+/- Pim-1-/- (n=23). The growth and weight was 
measured at age 6 weeks, with no significant differences between the four groups. None of 
the four groups showed any macroscopic abnormalities and the groups showed a similar 
survival rate up to the age of analysis (6-8 weeks). We were not able to show a reduction of 
Rps19 transcript levels in the Rps19+/- Pim-1+/+ and Rps19+/- Pim-1-/- mice as previously 
described 25 (data not shown). Pim-1 transcript levels were fully knocked down in the 
Rps19+/+ Pim-1-/- and Rps19+/- Pim-1-/- mice as expected (data not shown). 
Functional consequences of the targeted genes were further assessed in peripheral blood. We 
analyzed the standard parameters Hb, RBC, EVF, MCV, MCHC and WBC (table 1) from a 
total of 83 adult mice (Rps19+/+ Pim-1+/+ (wild type. n=22), Rps19+/- Pim-1+/+ (n=13), Rps19+/+ 
Pim-1-/- (n=25) and Rps19+/- Pim-1-/-(n=23)). RBC and WBC were found significantly 
increased in double mutant mice (Rps19+/- Pim-1-/-) when compared to wild type mice (table 
1). No significant differences were found for RBC or WBC when comparing either of the 
single Rps19+/- or the Pim-1-/- disruptions to the wild type mice. Microcytosis was previously 
associated with Pim1 deficiency and found to be similar in the single Pim-1-/- mutant mice as 
well as the double mutant mice (Rps19+/- Pim-1-/-). The Hb levels were subnormal in the 
double mutant Rps19+/- Pim-1-/- mice but significantly increased when compared to the Pim-1 
deficient mice (table1). Similarly, the hematocrit was subnormal in the double mutant mice 
but significantly increased when compared to the single Pim-1 mutant mice. MCHC showed a 
tendency towards lower levels in the double mutant mice compared to the Pim-1 null mutant 
mice and the wild type but the variations are large within groups and no significant 
differences were detected. There were no histopathological differences when analyzing the 
BM and spleen (data not shown) 
 
Rps19 and Pim-1 have a combined effect on cell cycle regulators 
To further clarify the increased peripheral cellularity we analyzed the levels of the cell cycle 
regulators c-Myc and p21 as well as the tumor suppressor protein p53. BM cells were 
harvested from murine femurs and proteins were prepared and subjected to Western blot 
analysis. After correlation to beta-actin levels we detect a significant up-regulation of c-Myc 
(p<0.01) levels in the double mutant (Rps19+/- Pim-1-/-) mice when comparing to the three 
other groups and a significant down-regulation of p21 (p<0.05) levels in the Rps19+/- Pim-1-/-
mice when comparing to Rps19+/+ Pim-1+/+ mice (Figure 1A-B). When analyzing the levels of 
p53 we do not detect any differences between the four different groups (Figure 1C).  
 
Combined disruption of Rps19 and Pim-1 alters the levels of apoptotic factors 
We next analyzed apoptotic factors in BM cells to substantiate the findings from the cell cycle 
regulators. We selected anti-apoptotic markers (Bcl2, BclXL and Mcl-1) and apoptotic markers 
(Bak and cleaved Caspase 3) for analysis by Western blot. We detect a significant up-
regulation of the anti-apoptotic markers Bcl2 (p<0.05) and Mcl-1 (p<0.05) in the double 
mutant (Rps19+/- Pim-1-/-) mice when comparing to Rps19+/+ Pim-1+/+ and Rps19+/- Pim-1+/+ 
mice, respectively (Figures 2A and B). Similarly, we find a significant up-regulation in BclXL 
(p<0.05) in the double mutant (Rps19+/- Pim-1-/-) mice when comparing to Rps19+/+ Pim-1+/+ 
mice (Figure 2C). We also detect a significant down-regulation of the apoptotic marker Bak 
(p<0.001) when comparing the double mutant (Rps19+/- Pim-1-/-) mice to the other three 
groups, (Figure 2D) after normalization to beta-actin. Similarly, we find a significant down-
regulation of cleaved Caspase 3 (p<0.05) in the double mutant (Rps19+/- Pim-1-/-) mice when 
comparing to Rps19+/+ Pim-1+/+ and Rps19+/+ Pim-1-/- mice, respectively (Figure 2E).  
 
Discussion 
 
To investigate the function of the RPS19 and PIM-1 interaction we generated different 
combinations of Rps19 and Pim-1 genotypes by interbreeding the Rps19+/- and Pim-1-/- mice 
strains 18,25. None of the four selected groups (Rps19+/+ Pim-1+/+, Rps19+/- Pim-1+/+, Rps19+/+ 
Pim-1-/- and Rps19+/- Pim-1-/-) showed any detectable morphological or histopathological 
abnormalities in the BM or spleen. Next, we investigated peripheral blood from mice with the 
four different genotypes at 6-8 weeks of age for the standard parameters Hb, RBC, EVF, 
MCV, MCHC and WBC (table 1). The double mutant (Rps19+/- Pim-1-/-) mice show increased 
RBC and WBC counts in peripheral blood when compared to the two single mutant (Rps19+/- 
Pim-1+/+, Rps19+/+ Pim-1-/-) mice strains and wild type (Rps19+/+ Pim-1+/+). Microcytosis, 
which is associated with Pim-1 deficiency 18, was confirmed in the single Pim-1-/- mutant 
mice as well as the double mutant (Rps19+/- Pim-1-/-) mice. Despite an increased RBC count, 
the double mutant mice display subnormal Hb and EVF which is less pronounced when 
compared to Pim-1 deficient mice. These findings suggest that the interaction between RPS19 
and PIM-1 13 has an effect on proliferation and/or survival of RBC and WBC.  
The increased myeloid cellularity in Rps19+/- Pim-1-/- mice is associated with an up-regulation 
of c-Myc. Neither Pim-1 deficiency nor Rps19 haploinsufficiency alone did result in 
deregulation of c-Myc. It has been shown that c-Myc cooperates with Pim-1; Pim-1 
phosphorylates histones required for c-Myc dependent transcription 20 and Pim-1 
phosphorylates c-Myc itself 19. In addition, c-Myc have been shown to directly promote 
ribosome biogenesis through the transcriptional regulation of ribosomal proteins, RNA 
polymerase I and III and factors involved in ribosome assembly 28,29. On the other hand, c-
Myc activity is suppressed by the ribosomal protein L11 30 and by ribosomal protein L24 
haploinsufficiency 31. These results indicate a crosstalk between the c-Myc induced cell 
growth and the translational machinery. Thus, the increased levels of c-Myc observed in 
Rps19+/- Pim-1-/- mice may be related to a loss of a feedback mechanism involving both 
Rps19 and Pim-1.  
c-Myc is essential for hematopoietic stem-cell renewal and cell progression 32. In addition, c-
Myc sensitizes cells to apoptosis through the mitochondrial apoptosis pathway. c-Myc primes 
a molecular switch of the Bcl-2 family of proteins resulting in a activation of the apoptotic 
factors Bak-Bax whereas the antagonistic factors Bcl2, BclXL and Mcl-1 are suppressed 33. 
Over-expression of Bcl-2 has in early experiments shown to block c-Myc induced apoptosis 
without inhibiting cell cycle progression 34,35. Unexpectedly, we observe an up-regulation of 
the anti-apoptotic factors Bcl2, BclXL and Mcl-1 in the double mutant (Rps19+/- Pim-1-/-) mice. 
This was found associated with a down-regulation of the apoptotic protein Bak and the more 
downstream factor Caspase 3 consistent with the known inhibitory effects of Bcl2, BclXL and 
Mcl-1 on Bak-Bax. These findings indicate that the Rps19+/- Pim-1-/- mice has an altered 
balance between pro-apoptotic and anti-apoptotic Bcl family members resulting in reduced 
apoptosis. 
c-Myc expression suppresses the cell cycle regulator p21 36 and we confirmed a marked 
reduction of p21 levels in the Rps19+/- Pim-1-/- mice. The suppression of p21 in combination 
with the observed normal levels of p53 indicates that the BM cells are not under stress. The 
promoting effect of c-Myc on cell cycle progression and cell growth together with the altered 
balance between Bcl-2 family of proteins may then result in the increased myeloid cellularity 
observed in Rps19+/- Pim-1-/- mice. From our results, we suggest an inter-dependent effect of 
Rps19 and Pim-1 as sensitizers in murine myeloid cell growth. We hypothesize that the 
combination of Rps19 insufficiency and Pim-1 deficiency result in the loss of a regulatory 
loop involving c-Myc. Simultaneously, Rps19 insufficiency and Pim-1 deficiency seems to 
suppress the c-Myc induced apoptotic switch. As a result, cell cycle progression and cell 
survival is promoted consistent with the increased peripheral cellularity observed in the 
Rps19+/-Pim-1-/- mice.  
In conclusion, our combined data show that allelic Rps19 insufficiency and Pim-1 deficiency 
have a co-operative effect on murine hematopoiesis resulting in an increased peripheral 
erythroid and myeloid cellularity. This is associated with deregulated c-Myc levels, 
expression of anti-apoptotic markers and suppression of p21. RPS19 insufficiency in DBA is 
associated with increased disposition for MDS and AML which presumably requires a 
combination of mutations. We suggest that candidate target genes in this progression encode 
cell cycle regulators or anti-apoptotic factors with functions analogous to those of PIM-1. 
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Table 1. Peripheral blood parameters from adult mice  with the genotypes Rps19+/+ Pim-1+/+ (w.t.), Rps19+/- 
Pim-1+/+, Rps19+/+Pim-1-/-, Rps19+/- Pim-1-/-. 
 
 
a SD, standard deviation; n, number of mice analyzed. 
b P < 0.05 (two-tailed unpaired student t-test compared to wild type). 
c Abbreviations: RBC, red blood cell count; WBC, white blood cell count; Hb, hemoglobin; EVF, hematocrit; 
MCV, mean corpuscular volume; MCHC, mean corpuscular hemoglobin concentration. 
 Mean value ± SD in mice (n)a
 Rps19+/+Pim-1+/+ Rps19+/-Pim-1+/+ Rps19+/+Pim-1-/- Rps19+/-Pim-1-/- 
RBCc (1012cells/L) 9,55±0,56 (22) 9,87±0,53 (13) 9,70±0,53 (25) 10,02±0,39 (23)b
WBCc (109cells/L) 4,75±1,33 (22) 5,92±2,63 (13) 5,20±1,45 (25) 6,06±1,88 (23)b
Hbc (g/L) 154,50±9,38 (22) 154,75±8,04 (13) 142,35±6,36 (25)b 146,90±5,18 (23)b
EVFc 0,51±0,03 (22) 0,52±0,02 (13) 0,48±0,03 (25)b 0,49±0,03 (23)b
MCVc (fL) 53,24±2,30 (22) 52,50±2,07 (13) 48,96±2,85 (25)b 49,13±3,00 (23)b
MCHCc (g/L) 304,15±9,83 (22) 300,54±9,24 (13) 301,44±13,34 (25) 299,00±11,48 (23) 
Figure 1. Analysis of cell cycle regulators in mice BM cells. Western blot analysis of total BM proteins. Each 
protein measurement was normalized to beta-actin. Blots with mean values ±std from at least two independent 
measurements are shown. (A) c-Myc levels is significantly up-regulated (** p<0.01) in the double mutant 
(Rps19+/- Pim-1-/-) mice when compared to the other three groups. (B) p21 levels is significantly down-regulated 
(* p<0.05) in the double mutant (Rps19+/- Pim-1-/-) mice when compared to w.t. mice. (C) No altered p53 levels 
are found. 
Figure 2. Analysis of apoptotic markers in mice BM cells. Western blot analysis of total BM proteins. Each 
protein measurement was normalized to beta-actin. Blots with mean values ±std from at least two independent 
measurements are shown. (A) The anti-apoptotic marker, Bcl2, was found significantly up-regulated (* p<0.05) 
in the double mutant (Rps19+/- Pim-1-/-) mice when compared to w.t. and Rps19+/- Pim-1+/+ mice. (B) The anti-
apoptotic marker, Mcl-1, was found significantly up-regulated (* p<0.05) in the double mutant (Rps19+/- Pim-1-/-
) mice when compared to w.t. and Rps19+/- Pim-1+/+ mice. (C) The anti-apoptotic marker, BclXL, was found 
significantly up-regulated (* p<0.05) in the double mutant (Rps19+/- Pim-1-/-) mice when compared to w.t. mice. 
(D) The pro-apoptotic marker, Bak, was found significantly down-regulated (*** p<0.001) in the double mutant 
(Rps19+/- Pim-1-/-) mice when compared to the other three groups. (E) The pro-apoptotic marker, cleaved 
Caspase 3, was found significantly down-regulated (* p<0.05) in the double mutant (Rps19+/- Pim-1-/-) mice 
when compared to w.t. and Rps19+/+ Pim-1-/- mice.  
 


